T-cell immunity to influenza a viruses

Critical Reviews in Immunology

Volumn 34, Issue 1, 2014, Pages 15-39

  Grant, Emma J ^a   Chen, Li ^b,c   Quiñones Parra, Sergio ^a   Pang, Ken ^a,d   Kedzierska, Katherine ^a   Chen, Weisan ^c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c LA TROBE UNIVERSITY   (Australia)

^d WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Epitope; HLA; Influenza; T cell; Vaccine

Indexed keywords

CYTOKINE; EPITOPE; FLU V VACCINE; HLA ANTIGEN CLASS 1; INFLUENZA VACCINE; T LYMPHOCYTE ANTIGEN; UNCLASSIFIED DRUG; VACCINIA VACCINE; VIRUS ANTIGEN;

AMINO ACID SEQUENCE; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN PRESENTING CELL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CROSS REACTION; CYTOKINE PRODUCTION; GENETIC POLYMORPHISM; HLA SYSTEM; HUMAN; HUMORAL IMMUNITY; IMMUNE EVASION; IMMUNIZATION; INFLUENZA A; INFLUENZA VIRUS A; NONHUMAN; PRIORITY JOURNAL; T CELL DEPLETION; T LYMPHOCYTE; VIRAL CLEARANCE; VIRUS CELL INTERACTION;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENIC VARIATION; ANTIGENS, VIRAL; DISEASE MODELS, ANIMAL; HUMANS; IMMUNODOMINANT EPITOPES; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; ORTHOMYXOVIRIDAE INFECTIONS; T-LYMPHOCYTES;

EID: 84896866265     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevImmunol.2013010019     Document Type: Article

References (184)

1. Razuri H, Romero C, Tinoco Y, Guezala MC, Ortiz E, Silva M, Reaves E, Williams M, Laguna-Torres VA, Halsey ES, Gomez J, Azziz-Baumgartner E, Widdowson MA, Bresee J, Moen A, Uyeki TM, Bennett A, Montgomery JM, Bausch DG. Population-based active surveillance cohort studies for influenza: lessons from Peru. Bull World Health Organ. 2012; 90 (4): 318-20.
2. McKinstry KK, Dutton RW, Swain SL, Strutt TM. Memory CD4 T cell-mediated immunity against influenza A virus: more than a little helpful. Arch Immunol Ther Exp (Warsz). 2013; 61 (5): 341-53.
3. McElhaney JE, Xie D, Hager WD, Barry MB, Wang Y, Kleppinger A, Ewen C, Kane KP, Bleackley RC. T cell responses are better correlates of vaccine protection in the elderly. J Immunol. 2006; 176 (10): 6333-9.
4. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science. 1996; 272 (5258): 60-6.
5. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998; 392 (6673): 245-52.
6. Hamada H, Bassity E, Flies A, Strutt TM, Garcia-Hernandez Mde L, McKinstry KK, Zou T, Swain SL, Dutton RW. Multiple redundant effector mechanisms of CD8+ T cells protect against influenza infection. J Immunol. 2013; 190 (1): 296-306.
7. Kedzierska K, Rimmelzwaan GF. Virus infections: T cells come to the rescue. Curr Opin Virol. 2013; 3 (4): 422-4.
8. Topham DJ, Tripp RA, Doherty PC. CD8+ T cells clear influenza virus by perforin or Fas-dependent processes. J Immunol. 1997; 159 (11): 5197-200.
9. Andrade F. Non-cytotoxic antiviral activities of granzymes in the context of the immune antiviral state. Immunol Rev. 2010; 235 (1): 128-46.
10. Trapani JA, Smyth MJ. Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol. 2002; 2 (10): 735-47.
11. Valkenburg SA, Rutigliano JA, Ellebedy AH, Doherty PC, Thomas PG, Kedzierska K. Immunity to seasonal and pandemic influenza A viruses. Microbes Infect. 2011; 13 (5): 489-501.
12. Sun J, Braciale TJ. Role of T cell immunity in recovery from influenza virus infection. Curr Opin Virol. 2013; 3 (4): 425-9.
13. Brincks EL, Katewa A, Kucaba TA, Griffith TS, Legge KL. CD8 T cells utilize TRAIL to control influenza virus infection. J Immunol. 2008; 181 (7): 4918-25.
14. Kreijtz JH, Fouchier RA, Rimmelzwaan GF. Immune responses to influenza virus infection. Virus Res. 2011; 162 (1-2): 19-30.
15. Murali-Krishna K, Altman JD, Suresh M, Sourdive DJ, Zajac AJ, Miller JD, Slansky J, Ahmed R. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity. 1998; 8 (2): 177-87.
16. Kedzierska K, Valkenburg SA, Doherty PC, Davenport MP, Venturi V. Use it or lose it: establishment and persistence of T cell memory. Front Immunol. 2012; 3: 357.
17. Miller JD, van der Most RG, Akondy RS, Glidewell JT, Albott S, Masopust D, Murali-Krishna K, Mahar PL, Edupuganti S, Lalor S, Germon S, Del Rio C, Mulligan MJ, Staprans SI, Altman JD, Feinberg MB, Ahmed R. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity. 2008; 28 (5): 710-22.
18. Akondy RS, Monson ND, Miller JD, Edupuganti S, Teuwen D, Wu H, Quyyumi F, Garg S, Altman JD, Del Rio C, Keyserling HL, Ploss A, Rice CM, Orenstein WA, Mulligan MJ, Ahmed R. The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J Immunol. 2009; 183 (12): 7919-30.
19. Yap KL, Ada GL, McKenzie IF. Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus. Nature. 1978; 273 (5659): 238-9.
20. Wells MA, Albrecht P, Ennis FA. Recovery from a viral respiratory infection. I. Influenza pneumonia in normal and T-deficient mice. J Immunol. 1981; 126 (3): 1036-41.
21. Bender BS, Croghan T, Zhang L, Small PA Jr. Transgenic mice lacking class I major histocompatibility complexrestricted T cells have delayed viral clearance and increased mortality after influenza virus challenge. J Exp Med. 1992; 175 (4): 1143-5.
22. Taylor PM, Askonas BA. Influenza nucleoprotein-specific cytotoxic T-cell clones are protective in vivo. Immunology. 1986; 58 (3): 417-20.
23. Nguyen HH, Moldoveanu Z, Novak MJ, van Ginkel FW, Ban E, Kiyono H, McGhee JR, Mestecky J. Heterosubtypic immunity to lethal influenza A virus infection is associated with virus-specific CD8 (+) cytotoxic T lymphocyte responses induced in mucosaassociated tissues. Virology. 1999; 254 (1): 50-60.
24. McMichael AJ, Gotch FM, Noble GR, Beare PA. Cytotoxic T-cell immunity to influenza. New Engl J Med. 1983; 309 (1): 13-7.
25. Lee LY, Ha do LA, Simmons C, de Jong MD, Chau NV, Schumacher R, Peng YC, McMichael AJ, Farrar JJ, Smith GL, Townsend AR, Askonas BA, Rowland-Jones S, Dong T. Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J Clin Invest. 2008; 118 (10): 3478-90.
26. Kreijtz JH, de Mutsert G, van Baalen CA, Fouchier RA, Osterhaus AD, Rimmelzwaan GF. Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus. J Virol. 2008; 82 (11): 5161-6.
27. Tu W, Mao H, Zheng J, Liu Y, Chiu SS, Qin G, Chan PL, Lam KT, Guan J, Zhang L, Guan Y, Yuen KY, Peiris JS, Lau YL. Cytotoxic T lymphocytes established by seasonal human influenza cross-react against 2009 pandemic H1N1 influenza virus. J Virol. 2010; 84 (13): 6527-35.
28. Hillaire ML, Vogelzang-van Trierum SE, Kreijtz JH, de Mutsert G, Fouchier RA, Osterhaus AD, Rimmelzwaan GF. Human T-cells directed to seasonal influenza A virus cross-react with 2009 pandemic influenza A (H1N1) and swine-origin triple-reassortant H3N2 influenza viruses. J Gen Virol. 2013; 94 (Pt 3): 583-92.
29. Sridhar S, Begom S, Bermingham A, Hoschler K, Adamson W, Carman W, Bean T, Barclay W, Deeks JJ, Lalvani A. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat Med. 2013; 19 (10): 1305-12.
30. Boyden AW, Legge KL, Waldschmidt TJ. Pulmonary infection with influenza A virus induces site-specific germinal center and T follicular helper cell responses. PLoS One. 2012; 7 (7): e40733.
31. Sun JC, Bevan MJ. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science. 2003; 300 (5617): 339-42.
32. Swain SL, Agrewala JN, Brown DM, Jelley-Gibbs DM, Golech S, Huston G, Jones SC, Kamperschroer C, Lee WH, McKinstry KK, Roman E, Strutt T, Weng NP. CD4+ T-cell memory: generation and multi-faceted roles for CD4+ T cells in protective immunity to influenza. Immunol Rev. 2006; 211: 8-22.
33. Swain SL, McKinstry KK, Strutt TM. Expanding roles for CD4 (+) T cells in immunity to viruses. Nat Rev Immunol. 2012; 12 (2): 136-48.
34. Teijaro JR, Verhoeven D, Page CA, Turner D, Farber DL. Memory CD4 T cells direct protective responses to influenza virus in the lungs through helper-independent mechanisms. J Virol. 2010; 84 (18): 9217-26.
35. Brown DM, Lee S, Garcia-Hernandez Mde L, Swain SL. Multifunctional CD4 cells expressing gamma interferon and perforin mediate protection against lethal influenza virus infection. J Virol. 2012; 86 (12): 6792-803.
36. McKinstry KK, Strutt TM, Kuang Y, Brown DM, Sell S, Dutton RW, Swain SL. Memory CD4+ T cells protect against influenza through multiple synergizing mechanisms. J Clin Invest. 2012; 122 (8): 2847-56.
37. Wilkinson TM, Li CK, Chui CS, Huang AK, Perkins M, Liebner JC, Lambkin-Williams R, Gilbert A, Oxford J, Nicholas B, Staples KJ, Dong T, Douek DC, McMichael AJ, Xu XN. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med. 2012; 18 (2): 274-80.
38. Brown DM, Dilzer AM, Meents DL, Swain SL. CD4 T cell-mediated protection from lethal influenza: perforin and antibody-mediated mechanisms give a one-two punch. J Immunol. 2006; 177 (5): 2888-98.
39. Soghoian DZ, Streeck H. Cytolytic CD4 (+) T cells in viral immunity. Expert Rev Vaccines. 2010; 9 (12): 1453-63.
40. Strutt TM, McKinstry KK, Dibble JP, Winchell C, Kuang Y, Curtis JD, Huston G, Dutton RW, Swain SL. Memory CD4+ T cells induce innate responses independently of pathogen. Nat Med. 2010; 16 (5): 558-64, 1p following 64.
41. Belz GT, Wodarz D, Diaz G, Nowak MA, Doherty PC. Compromised influenza virus-specific CD8 (+)-Tcell memory in CD4 (+)-T-cell-deficient mice. J Virol. 2002; 76 (23): 12388-93.
42. Teijaro JR, Njau MN, Verhoeven D, Chandran S, Nadler SG, Hasday J, Farber DL. Costimulation modulation uncouples protection from immunopathology in memory T cell responses to influenza virus. J Immunol. 2009; 182 (11): 6834-43.
43. Leone P, Shin EC, Perosa F, Vacca A, Dammacco F, Racanelli V. MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells. J Natl Cancer Inst. 2013; 105 (16): 1172-87.
44. Yewdell JW, Schubert U, Bennink JR. At the crossroads of cell biology and immunology: DRiPs and other sources of peptide ligands for MHC class I molecules. J Cell Sci. 2001; 114 (Pt 5): 845-51.
45. Pamer E, Cresswell P. Mechanisms of MHC class I-restricted antigen processing. Annu Rev Immunol. 1998; 16: 323-58.
46. Germain RN, Margulies DH. The biochemistry and cell biology of antigen processing and presentation. Annu Rev Immunol. 1993; 11: 403-50.
47. Davis MM, Bjorkman PJ. T-cell antigen receptor genes and T-cell recognition. Nature. 1988; 334 (6181): 395-402.
48. La Gruta NL, Thomas PG. Interrogating the relationship between naive and immune antiviral T cell repertoires. Curr Opin Virol. 2013; 3 (4): 447-51.
49. Turner SJ, Doherty PC, McCluskey J, Rossjohn J. Structural determinants of T-cell receptor bias in immunity. Nat Rev Immunol. 2006; 6 (12): 883-94.
50. Arstila TP, Casrouge A, Baron V, Even J, Kanellopoulos J, Kourilsky P. A direct estimate of the human alphabeta T cell receptor diversity. Science. 1999; 286 (5441): 958-61.
51. Chen W, Calvo PA, Malide D, Gibbs J, Schubert U, Bacik I, Basta S, O'Neill R, Schickli J, Palese P, Henklein P, Bennink JR, Yewdell JW. A novel influenza A virus mitochondrial protein that induces cell death. Nat Med. 2001; 7 (12): 1306-12.
52. Jagger BW, Wise HM, Kash JC, Walters KA, Wills NM, Xiao YL, Dunfee RL, Schwartzman LM, Ozinsky A, Bell GL, Dalton RM, Lo A, Efstathiou S, Atkins JF, Firth AE, Taubenberger JK, Digard P. An overlapping proteincoding region in influenza A virus segment 3 modulates the host response. Science. 2012; 337 (6091): 199-204.
53. Yewdell JW, Bennink JR. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu Rev Immunol. 1999; 17: 51-88.
54. Gonzalez-Galarza FF, Christmas S, Middleton D, Jones AR. Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res. 2011; 39 (Database issue): D913-9.
55. Lienert K, McCluskey J, Bennett G, Fowler C, Russ G. HLA class I variation in Australian aborigines: characterization of allele B*1521. Tissue Antigens. 1995; 45 (1): 12-7.
56. Gao X, Lester S, Matheson B, Boettcher B, McCluskey J. Three newly identified A*24 alleles: A*2406, A*2413 and A*2414. Tissue Antigens. 1997; 50 (2): 192-6.
57. Townsend AR, Rothbard J, Gotch FM, Bahadur G, Wraith D, McMichael AJ. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell. 1986; 44 (6): 959-68.
58. McMichael AJ, Gotch FM, Rothbard J. HLA B37 determines an influenza A virus nucleoprotein epitope recognized by cytotoxic T lymphocytes. J Exp Med. 1986; 164 (5): 1397-406.
59. Gotch F, McMichael A, Smith G, Moss B. Identification of viral molecules recognized by influenza-specific human cytotoxic T lymphocytes. J Exp Med. 1987; 165 (2): 408-16.
60. Falk K, Rotzschke O, Rammensee HG. Cellular peptide composition governed by major histocompatibility complex class I molecules. Nature. 1990; 348 (6298): 248-51.
61. Jardetzky TS, Lane WS, Robinson RA, Madden DR, Wiley DC. Identification of self peptides bound to purified HLA-B27. Nature. 1991; 353 (6342): 326-9.
62. Hunt DF, Henderson RA, Shabanowitz J, Sakaguchi K, Michel H, Sevilir N, Cox AL, Appella E, Engelhard VH. Characterization of peptides bound to the class I MHC molecule HLA-A2. 1 by mass spectrometry. Science. 1992; 255 (5049): 1261-3.
63. Wahl A, Schafer F, Bardet W, Buchli R, Air GM, Hildebrand WH. HLA class I molecules consistently present internal influenza epitopes. Proc Natl Acad Sci U S A. 2009; 106 (2): 540-5.
64. Chen W, Yewdell JW, Levine RL, Bennink JR. Modification of cysteine residues in vitro and in vivo affects the immunogenicity and antigenicity of major histocompatibility complex class I-restricted viral determinants. J Exp Med. 1999; 189 (11): 1757-64.
65. Wu C, Zanker D, Valkenburg S, Tan B, Kedzierska K, Zou QM, Doherty PC, Chen W. Systematic identification of immunodominant CD8+ T-cell responses to influenza A virus in HLA-A2 individuals. Proc Natl Acad Sci U S A. 2011; 108 (22): 9178-83.
66. Grant E, Wu C, Chan KF, Eckle S, Bharadwaj M, Zou QM, Kedzierska K, Chen W. Nucleoprotein of influenza A virus is a major target of immunodominant CD8+ T-cell responses. Immunol Cell Biol. 2013; 91 (2): 184-94.
67. Testa JS, Shetty V, Hafner J, Nickens Z, Kamal S, Sinnathamby G, Philip R. MHC class I-presented T cell epitopes identified by immunoproteomics analysis are targets for a cross reactive influenza-specific T cell response. PLoS One. 2012; 7 (11): e48484.
68. Gianfrani C, Oseroff C, Sidney J, Chesnut RW, Sette A. Human memory CTL response specific for influenza A virus is broad and multispecific. Hum Immunol. 2000; 61 (5): 438-52.
69. Sun Y, Liu J, Yang M, Gao F, Zhou J, Kitamura Y, Gao B, Tien P, Shu Y, Iwamoto A, Chen Z, Gao GF. Identification and structural definition of H5-specific CTL epitopes restricted by HLA-A* 0201 derived from the H5N1 subtype of influenza A viruses. J Gen Virol. 2010; 91 (Pt 4): 919-30.
70. Kosor Krnic E, Gagro A, Drazenovic V, Kuzman I, Jeren T, Cecuk-Jelicic E, Kerhin-Brkljacic V, Gjenero-Margan I, Kaic B, Rakusic S, Sabioncello A, Markotic A, Rabatic S, Mlinaric-Galinovic G, Dekaris D. Enumeration of haemagglutinin-specific CD8+ T cells after influenza vaccination using MHC class I peptide tetramers. Scand J Immunol. 2008; 67 (1): 86-94.
71. Assarsson E, Bui HH, Sidney J, Zhang Q, Glenn J, Oseroff C, Mbawuike IN, Alexander J, Newman MJ, Grey H, Sette A. Immunomic analysis of the repertoire of T-cell specificities for influenza A virus in humans. J Virol. 2008; 82 (24): 12241-51.
72. Wedemeyer H, Mizukoshi E, Davis AR, Bennink JR, Rehermann B. Cross-reactivity between hepatitis C virus and Influenza A virus determinant-specific cytotoxic T cells. J Virol. 2001; 75 (23): 11392-400.
73. Alexander J, Bilsel P, del Guercio MF, Marinkovic-Petrovic A, Southwood S, Stewart S, Ishioka G, Kotturi MF, Botten J, Sidney J, Newman M, Sette A. Identification of broad binding class I HLA supertype epitopes to provide universal coverage of influenza A virus. Hum Immunol. 2010; 71 (5): 468-74.
74. Trojan A, Urosevic M, Hummerjohann J, Giger R, Schanz U, Stahel RA. Immune reactivity against a novel HLA-A3-restricted influenza virus peptide identified by predictive algorithms and interferon-gamma quantitative PCR. J Immunother. 2003; 26 (1): 41-6.
75. Bodmer HC, Gotch FM, McMichael AJ. Class I crossrestricted T cells reveal low responder allele due to processing of viral antigen. Nature. 1989; 337 (6208): 653-5.
76. Bednarek MA, Sauma SY, Gammon MC, Porter G, Tamhankar S, Williamson AR, Zweerink HJ. The minimum peptide epitope from the influenza virus matrix protein. Extra and intracellular loading of HLA-A2. J Immunol. 1991; 147 (12): 4047-53.
77. Kasprowicz V, Ward SM, Turner A, Grammatikos A, Nolan BE, Lewis-Ximenez L, Sharp C, Woodruff J, Fleming VM, Sims S, Walker BD, Sewell AK, Lauer GM, Klenerman P. Defining the directionality and quality of influenza virus-specific CD8+ T cell cross-reactivity in individuals infected with hepatitis C virus. J Clin Invest. 2008; 118 (3): 1143-53.
78. Liu J, Zhang S, Tan S, Yi Y, Wu B, Cao B, Zhu F, Wang C, Wang H, Qi J, Gao GF. Cross-allele cytotoxic T lymphocyte responses against 2009 pandemic H1N1 influenza A virus among HLA-A24 and HLA-A3 supertype-positive individuals. J Virol. 2012; 86 (24): 13281-94.
79. Dong T, Boyd D, Rosenberg W, Alp N, Takiguchi M, McMichael A, Rowland-Jones S. An HLA-B35-restricted epitope modified at an anchor residue results in an antagonist peptide. Eur J Immunol. 1996; 26 (2): 335-9.
80. Wang M, Lamberth K, Harndahl M, Roder G, Stryhn A, Larsen MV, Nielsen M, Lundegaard C, Tang ST, Dziegiel MH, Rosenkvist J, Pedersen AE, Buus S, Claesson MH, Lund O. CTL epitopes for influenza A including the H5N1 bird flu; genome-, pathogen-, and HLA-wide screening. Vaccine. 2007; 25 (15): 2823-31.
81. Jameson J, Cruz J, Ennis FA. Human cytotoxic T-lymphocyte repertoire to influenza A viruses. J Virol. 1998; 72 (11): 8682-9.
82. DiBrino M, Tsuchida T, Turner RV, Parker KC, Coligan JE, Biddison WE. HLA-A1 and HLA-A3 T cell epitopes derived from influenza virus proteins predicted from peptide binding motifs. J Immunol. 1993; 151 (11): 5930-5.
83. Cheung YK, Cheng SC, Ke Y, Xie Y. Human immunogenic T cell epitopes in nucleoprotein of human influenza A (H5N1) virus. Hong Kong Med J. 2012; 18 (Suppl 2): 17-21.
84. Cerundolo V, Tse AG, Salter RD, Parham P, Townsend A. CD8 independence and specificity of cytotoxic T lymphocytes restricted by HLA-Aw68. 1. Proc Biol Sci. 1991; 244 (1310): 169-77.
85. Berkhoff EG, Geelhoed-Mieras MM, Fouchier RA, Osterhaus AD, Rimmelzwaan GF. Assessment of the extent of variation in influenza A virus cytotoxic T-lymphocyte epitopes by using virus-specific CD8+ T-cell clones. J Gen Virol. 2007; 88 (Pt 2): 530-5.
86. DiBrino M, Parker KC, Margulies DH, Shiloach J, Turner RV, Biddison WE, Coligan JE. The HLA-B14 peptide binding site can accommodate peptides with different combinations of anchor residues. J Biol Chem. 1994; 269 (51): 32426-34.
87. Carreno BM, Turner RV, Biddison WE, Coligan JE. Overlapping epitopes that are recognized by CD8+ HLA class I-restricted and CD4+ class II-restricted cytotoxic T lymphocytes are contained within an influenza nucleoprotein peptide. J Immunol. 1992; 148 (3): 894-9.
88. DiBrino M, Parker KC, Margulies DH, Shiloach J, Turner RV, Biddison WE, Coligan JE. Identification of the peptide binding motif for HLA-B44, one of the most common HLA-B alleles in the Caucasian population. Biochemistry. 1995; 34 (32): 10130-8.
89. Suhrbier A, Schmidt C, Fernan A. Prediction of an HLA B8-restricted influenza epitope by motif. Immunology. 1993; 79 (1): 171-3.
90. Tussey LG, Rowland-Jones S, Zheng TS, Androlewicz MJ, Cresswell P, Frelinger JA, McMichael AJ. Different MHC class I alleles compete for presentation of overlapping viral epitopes. Immunity. 1995; 3 (1): 65-77.
91. Carreno BM, Winter CC, Taurog JD, Hansen TH, Biddison WE. Residues in pockets B and F of HLA-B27 are critical in the presentation of an influenza A virus nucleoprotein peptide and influence the stability of peptide-MHC complexes. Int Immunol. 1993; 5 (4): 353-60.
92. Huet S, Nixon DF, Rothbard JB, Townsend A, Ellis SA, McMichael AJ. Structural homologies between two HLA B27-restricted peptides suggest residues important for interaction with HLA B27. Int Immunol. 1990; 2 (4): 311-6.
93. Boon AC, de Mutsert G, Graus YM, Fouchier RA, Sintnicolaas K, Osterhaus AD, Rimmelzwaan GF. The magnitude and specificity of influenza A virus-specific cytotoxic T-lymphocyte responses in humans is related to HLA-A and-B phenotype. J Virol. 2002; 76 (2): 582-90.
94. Boon AC, de Mutsert G, van Baarle D, Smith DJ, Lapedes AS, Fouchier RA, Sintnicolaas K, Osterhaus AD, Rimmelzwaan GF. Recognition of homo-and heterosubtypic variants of influenza A viruses by human CD8+ T lymphocytes. J Immunol. 2004; 172 (4): 2453-60.
95. Berkhoff EG, Geelhoed-Mieras MM, Verschuren EJ, van Baalen CA, Gruters RA, Fouchier RA, Osterhaus AD, Rimmelzwaan GF. The loss of immunodominant epitopes affects interferon-gamma production and lytic activity of the human influenza virus-specific cytotoxic T lymphocyte response in vitro. Clin Exp Immunol. 2007; 148 (2): 296-306.
96. Gras S, Kedzierski L, Valkenburg SA, Laurie K, Liu YC, Denholm JT, Richards MJ, Rimmelzwaan GF, Kelso A, Doherty PC, Turner SJ, Rossjohn J, Kedzierska K. Crossreactive CD8+ T-cell immunity between the pandemic H1N1-2009 and H1N1-1918 influenza A viruses. Proc Natl Acad Sci U S A. 2010; 107 (28): 12599-604.
97. Man S, Newberg MH, Crotzer VL, Luckey CJ, Williams NS, Chen Y, Huczko EL, Ridge JP, Engelhard VH. Definition of a human T cell epitope from influenza A non-structural protein 1 using HLA-A2. 1 transgenic mice. Int Immunol. 1995; 7 (4): 597-605.
98. Terajima M, Cruz J, Leporati AM, Orphin L, Babon JA, Co MD, Pazoles P, Jameson J, Ennis FA. Influenza A virus matrix protein 1-specific human CD8+ T-cell response induced in trivalent inactivated vaccine recipients. J Virol. 2008; 82 (18): 9283-7.
99. Hui DJ, Basner-Tschakarjan E, Chen Y, Davidson RJ, Buchlis G, Yazicioglu M, Pien GC, Finn JD, Haurigot V, Tai A, Scott DW, Cousens LP, Zhou S, De Groot AS, Mingozzi F. Modulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopes. Mol Ther. 2013; 21 (9): 1727-37.
100. Sidney J, Peters B, Frahm N, Brander C, Sette A. HLA class I supertypes: a revised and updated classification. BMC Immunology. 2008; 9: 1.
101. Rao X, Hoof I, Costa AI, van Baarle D, Kesmir C. HLA class I allele promiscuity revisited. Immunogenetics. 2011; 63 (11): 691-701.
102. Sette A, Sidney J. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and-B polymorphism. Immunogenetics. 1999; 50 (3-4): 201-12.
103. Heiny AT, Miotto O, Srinivasan KN, Khan AM, Zhang GL, Brusic V, Tan TW, August JT. Evolutionarily conserved protein sequences of influenza a viruses, avian and human, as vaccine targets. PLoS One. 2007; 2 (11): e1190.
104. Greenbaum J, Sidney J, Chung J, Brander C, Peters B, Sette A. Functional classification of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising degree of repertoire sharing across supertypes. Immunogenetics. 2011; 63 (6): 325-35.
105. Lamb JR, Eckels DD, Phelan M, Lake P, Woody JN. Antigen-specific human T lymphocyte clones: viral antigen specificity of influenza virus-immune clones. J Immunol. 1982; 128 (3): 1428-32.
106. Lamb JR, Green N. Analysis of the antigen specificity of influenza haemagglutinin-immune human T lymphocyte clones: identification of an immunodominant region for T cells. Immunology. 1983; 50 (4): 659-66.
107. Eckels DD, Sell TW, Bronson SR, Johnson AH, Hartzman RJ, Lamb JR. Human helper T-cell clones that recognize different influenza hemagglutinin determinants are restricted by different HLA-D region epitopes. Immunogenetics. 1984; 19 (5): 409-23.
108. Adler S, Frank R, Lanzavecchia A, Weiss S. T cell epitope analysis with peptides simultaneously synthesized on cellulose membranes: fine mapping of two DQ dependent epitopes. FEBS Lett. 1994; 352 (2): 167-70.
109. Gelder CM, Welsh KI, Faith A, Lamb JR, Askonas BA. Human CD4+ T-cell repertoire of responses to influenza A virus hemagglutinin after recent natural infection. J Virol. 1995; 69 (12): 7497-506.
110. Rothbard JB, Busch R, Howland K, Bal V, Fenton C, Taylor WR, Lamb JR. Structural analysis of a peptide-HLA class II complex: identification of critical interactions for its formation and recognition by T cell receptor. Int Immunol. 1989; 1 (5): 479-86.
111. Barber LD, Bal V, Lamb JR, O'Hehir RE, Yendle J, Hancock RJ, Lechler RI. Contribution of T-cell receptor-contacting and peptide-binding residues of the class II molecule HLA-DR4 Dw10 to serologic and antigen-specific T-cell recognition. Hum Immunol. 1991; 32 (2): 110-8.
112. Brown LR, Nygard NR, Graham MB, Bono C, Braciale VL, Gorka J, Schwartz BD, Braciale TJ. Recognition of the influenza hemagglutinin by class II MHC-restricted T lymphocytes and antibodies. I. Site definition and implications for antigen presentation and T lymphocyte recognition. J Immunol. 1991; 147 (8): 2677-84.
113. Krieger JI, Karr RW, Grey HM, Yu WY, O'Sullivan D, Batovsky L, Zheng ZL, Colon SM, Gaeta FC, Sidney J, et al. Single amino acid changes in DR and antigen define residues critical for peptide-MHC binding and T cell recognition. J Immunol. 1991; 146 (7): 2331-40.
114. Zeliszewski D, Dorval I, Golvano JJ, Prevost A, Borras-Cuesta F, Sterkers G. Sharing of four DR-beta sequence motifs between HLA-DRB*1601 and DRB1*1101 correlates with frequent degenerate T-cell recognition of HA306-320 peptide complexed to these two molecules. Scand J Immunol. 1996; 43 (2): 146-54.
115. James EA, Moustakas AK, Berger D, Huston L, Papadopoulos GK, Kwok WW. Definition of the peptide binding motif within DRB1*1401 restricted epitopes by peptide competition and structural modeling. Mol Immunol. 2008; 45 (9): 2651-9.
116. Sturniolo T, Bono E, Ding J, Raddrizzani L, Tuereci O, Sahin U, Braxenthaler M, Gallazzi F, Protti MP, Sinigaglia F, Hammer J. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat Biotechnol. 1999; 17 (6): 555-61.
117. Bui HH, Sidney J, Peters B, Sathiamurthy M, Sinichi A, Purton KA, Mothe BR, Chisari FV, Watkins DI, Sette A. Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications. Immunogenetics. 2005; 57 (5): 304-14.
118. Nielsen M, Lundegaard C, Lund O. Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method. BMC Bioinformatics. 2007; 8: 238.
119. Wang P, Sidney J, Dow C, Mothe B, Sette A, Peters B. A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput Biol. 2008; 4 (4): e1000048.
120. Nielsen M, Lund O. NN-align. An artificial neural network-based alignment algorithm for MHC class II peptide binding prediction. BMC Bioinformatics. 2009; 10: 296.
121. Schanen BC, De Groot AS, Moise L, Ardito M, McClaine E, Martin W, Wittman V, Warren WL, Drake DR 3rd. Coupling sensitive in vitro and in silico techniques to assess cross-reactive CD4 (+) T cells against the swineorigin H1N1 influenza virus. Vaccine. 2011; 29 (17): 3299-309.
122. Hoft DF, Babusis E, Worku S, Spencer CT, Lottenbach K, Truscott SM, Abate G, Sakala IG, Edwards KM, Creech CB, Gerber MA, Bernstein DI, Newman F, Graham I, Anderson EL, Belshe RB. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J Infect Dis. 2011; 204 (6): 845-53.
123. Chaves FA, Lee AH, Nayak JL, Richards KA, Sant AJ. The utility and limitations of current Web-available algorithms to predict peptides recognized by CD4 T cells in response to pathogen infection. J Immunol. 2012; 188 (9): 4235-48.
124. Roti M, Yang J, Berger D, Huston L, James EA, Kwok WW. Healthy human subjects have CD4+ T cells directed against H5N1 influenza virus. J Immunol. 2008; 180 (3): 1758-68.
125. Babon JA, Cruz J, Orphin L, Pazoles P, Co MD, Ennis FA, Terajima M. Genome-wide screening of human T-cell epitopes in influenza A virus reveals a broad spectrum of CD4 (+) T-cell responses to internal proteins, hemagglutinins, and neuraminidases. Hum Immunol. 2009; 70 (9): 711-21.
126. Yang J, Gebe JA, Huston L, James E, Tan V, Yue BB, Nepom GT, Kwok WW. H5N1 strain-specific hemagglutinin CD4+ T cell epitopes restricted by HLA DR4. Vaccine. 2009; 27 (29): 3862-9.
127. Babon JA, Cruz J, Ennis FA, Yin L, Terajima M. A human CD4+ T cell epitope in the influenza hemagglutinin is cross-reactive to influenza A virus subtypes and to influenza B virus. J Virol. 2012; 86 (17): 9233-43.
128. Powell TJ, Fox A, Peng Y, Quynh Mai le T, Lien VT, Hang NL, Wang L, Lee LY, Simmons CP, McMichael AJ, Farrar JJ, Askonas BA, Duong TN, Thai PQ, Thu Yen NT, Rowland-Jones SL, Hien NT, Horby P, Dong T. Identification of H5N1-specific T-cell responses in a high-risk cohort in vietnam indicates the existence of potential asymptomatic infections. J Infect Dis. 2012; 205 (1): 20-7.
129. Yang J, Huston L, Berger D, Danke NA, Liu AW, Disis ML, Kwok WW. Expression of HLA-DP0401 molecules for identification of DP0401 restricted antigen specific T cells. J Clin Immunol. 2005; 25 (5): 428-36.
130. Yang J, James EA, Huston L, Danke NA, Liu AW, Kwok WW. Multiplex mapping of CD4 T cell epitopes using class II tetramers. Clin Immunol. 2006; 120 (1): 21-32.
131. Sant AJ, Chaves FA, Krafcik FR, Lazarski CA, Menges P, Richards K, Weaver JM. Immunodominance in CD4 T-cell responses: implications for immune responses to influenza virus and for vaccine design. Expert Rev Vaccines. 2007; 6 (3): 357-68.
132. Shaw ML, Stone KL, Colangelo CM, Gulcicek EE, Palese P. Cellular proteins in influenza virus particles. PLoS Pathogens. 2008; 4 (6): e1000085.
133. Li P, Gregg JL, Wang N, Zhou D, O'Donnell P, Blum JS, Crotzer VL. Compartmentalization of class II antigen presentation: contribution of cytoplasmic and endosomal processing. Immunol Rev. 2005; 207: 206-17.
134. Zhou D, Li P, Lin Y, Lott JM, Hislop AD, Canaday DH, Brutkiewicz RR, Blum JS. Lamp-2a facilitates MHC class II presentation of cytoplasmic antigens. Immunity. 2005; 22 (5): 571-81.
135. Paludan C, Schmid D, Landthaler M, Vockerodt M, Kube D, Tuschl T, Munz C. Endogenous MHC class II processing of a viral nuclear antigen after autophagy. Science. 2005; 307 (5709): 593-6.
136. Schmid D, Pypaert M, Munz C. Antigen-loading compartments for major histocompatibility co-mplex class II molecules continuously receive input from autophagosomes. Immunity. 2007; 26 (1): 79-92.
137. Munz C. Antigen processing for MHC class II presentation via autophagy. Front Immunol. 2012; 3: 9.
138. Menendez-Benito V, Neefjes J. Autophagy in MHC class II presentation: sampling from within. Immunity. 2007; 26 (1): 1-3.
139. Richards KA, Topham D, Chaves FA, Sant AJ. Cutting edge: CD4 T cells generated from encounter with seasonal influenza viruses and vaccines have broad protein specificity and can directly recognize naturally generated epitopes derived from the live pandemic H1N1 virus. J Immunol. 2010; 185 (9): 4998-5002.
140. Richards KA, Chaves FA, Sant AJ. The memory phase of the CD4 T-cell response to influenza virus infection maintains its diverse antigen specificity. Immunology. 2011; 133 (2): 246-56.
141. Berkhoff EG, de Wit E, Geelhoed-Mieras MM, Boon AC, Symons J, Fouchier RA, Osterhaus AD, Rimmelzwaan GF. Functional constraints of influenza A virus epitopes limit escape from cytotoxic T lymphocytes. J Virol. 2005; 79 (17): 11239-46.
142. Berkhoff EG, de Wit E, Geelhoed-Mieras MM, Boon AC, Symons J, Fouchier RA, Osterhaus AD, Rimmelzwaan GF. Fitness costs limit escape from cytotoxic T lymphocytes by influenza A viruses. Vaccine. 2006; 24 (44-46): 6594-6.
143. Hensley SE, Das SR, Bailey AL, Schmidt LM, Hickman HD, Jayaraman A, Viswanathan K, Raman R, Sasisekharan R, Bennink JR, Yewdell JW. Hemagglutinin receptor binding avidity drives influenza A virus antigenic drift. Science. 2009; 326 (5953): 734-6.
144. Pircher H, Moskophidis D, Rohrer U, Burki K, Hengartner H, Zinkernagel R. Viral escape by selection of cytotoxic T cell-resistant virus variants in vivo. Nature. 1990; 346: 629-33.
145. Moore C, John M, James I, Christiansen F, Witt C, Mallal S. Evidence of HIV-1 adaptation to HLArestricted immune responses at a population level. Science. 2002; 296: 1439-43.
146. Fernandez C, Stratov I, De Rose R, Walsh K, Dale C, Smith M, Agy M, Hu S, Krebs K, Watkins D, O'connor D, Davenport M, Kent S. Rapid viral escape at an immunodominant simian-human imm-unodeficiency virus cytotoxic T-lymphocyte epitope exacts a dramatic fitness cost. J Virol. 2005; 79: 5721-31.
147. Voeten JT, Bestebroer TM, Nieuwkoop NJ, Fouchier RA, Osterhaus AD, Rimmelzwaan GF. Antigenic drift in the influenza A virus (H3N2) nucleoprotein and escape from recognition by cytotoxic T lymphocytes. J Virol. 2000; 74 (15): 6800-7.
148. Oldstone MB. How viruses escape from cytotoxic T lymphocytes: molecular parameters and players. Virology. 1997; 234 (2): 179-85.
149. van de Sandt CE, Kreijtz JH, Rimmelzwaan GF. Evasion of influenza A viruses from innate and adaptive immune responses. Viruses. 2012; 4 (9): 1438-76.
150. Del Val M, Schlicht HJ, Ruppert T, Reddehase MJ, Koszinowski UH. Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein. Cell. 1991; 66 (6): 1145-53.
151. Eisenlohr LC, Yewdell JW, Bennink JR. Flanking sequences influence the presentation of an endogenously synthesized peptide to cytotoxic T lymphocytes. J Exp Med. 1992; 175 (2): 481-7.
152. Milicic A, Price DA, Zimbwa P, Booth BL, Brown HL, Easterbrook PJ, Olsen K, Robinson N, Gileadi U, Sewell AK, Cerundolo V, Phillips RE. CD8+ T cell epitopeflanking mutations disrupt proteasomal processing of HIV-1 Nef. J Immunol. 2005; 175 (7): 4618-26.
153. Hahn YS, Hahn CS, Braciale VL, Braciale TJ, Rice CM. CD8+ T cell recognition of an endogenously processed epitope is regulated primarily by residues within the epitope. J Exp Med. 1992; 176 (5): 1335-41.
154. Rimmelzwaan GF, Berkhoff EG, Nieuwkoop NJ, Smith DJ, Fouchier RA, Osterhaus AD. Full restoration of viral fitness by multiple compensatory co-mutations in the nucleoprotein of influenza A virus cytotoxic T-lymphocyte escape mutants. J Gen Virol. 2005; 86 (Pt 6): 1801-5.
155. Rimmelzwaan GF, Berkhoff EG, Nieuwkoop NJ, Fouchier RA, Osterhaus AD. Functional compensation of a detrimental amino acid substitution in a cytotoxic-Tlymphocyte epitope of influenza a viruses by comutations. J Virol. 2004; 78 (16): 8946-9.
156. Marsh SGE, Parham P, Barber LD. The HLA factsbook. San Diego: Academic Press; 2000.
157. Wahl A, McCoy W, Schafer F, Bardet W, Buchli R, Fremont DH, Hildebrand WH. T-cell tolerance for variability in an HLA class I-presented influenza A virus epitope. J Virol. 2009; 83 (18): 9206-14.
158. Hillaire M, Rimmelzwaan G, Kreijtz J. Clearance of influenza virus infections by T cells: risk of collateral damage? Curr Opin Virol. 2013; 3 (4): 430-7.
159. Damjanovic D, Small CL, Jeyanathan M, McCormick S, Xing Z. Immunopathology in influenza virus infection: uncoupling the friend from foe. Clin Immunol. 2012; 144 (1): 57-69.
160. La Gruta NL, Kedzierska K, Stambas J, Doherty PC. A question of self-preservation: immunopathology in influenza virus infection. Immunol Cell Biol. 2007; 85 (2): 85-92.
161. Kuribayashi S, Sakoda Y, Kawasaki T, Tanaka T, Yamamoto N, Okamatsu M, Isoda N, Tsuda Y, Sunden Y, Umemura T, Nakajima N, Hasegawa H, Kida H. Excessive cytokine response to rapid proliferation of highly pathogenic avian influenza viruses leads to fatal systemic capillary leakage in chickens. PLoS One. 2013; 8 (7): e68375.
162. Baskin CR, Bielefeldt-Ohmann H, Tumpey TM, Sabourin PJ, Long JP, Garcia-Sastre A, Tolnay AE, Albrecht R, Pyles JA, Olson PH, Aicher LD, Rosenzweig ER, Murali-Krishna K, Clark EA, Kotur MS, Fornek JL, Proll S, Palermo RE, Sabourin CL, Katze MG. Early and sustained innate immune response defines pathology and death in nonhuman primates infected by highly pathogenic influenza virus. Proc Natl Acad Sci U S A. 2009; 106 (9): 3455-60.
163. de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, Chau TN, Hoang DM, Chau NV, Khanh TH, Dong VC, Qui PT, Cam BV, Ha do Q, Guan Y, Peiris JS, Chinh NT, Hien TT, Farrar J. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med. 2006; 12 (10): 1203-7.
164. Perrone LA, Szretter KJ, Katz JM, Mizgerd JP, Tumpey TM. Mice lacking both TNF and IL-1 receptors exhibit reduced lung inflammation and delay in onset of death following infection with a highly virulent H5N1 virus. J Infect Dis. 2010; 202 (8): 1161-70.
165. Damjanovic D, Divangahi M, Kugathasan K, Small CL, Zganiacz A, Brown EG, Hogaboam CM, Gauldie J, Xing Z. Negative regulation of lung inflammation and immunopathology by TNF-alpha during acute influenza infection. Am J Pathol. 2011; 179 (6): 2963-76.
166. Li C, Yang P, Sun Y, Li T, Wang C, Wang Z, Zou Z, Yan Y, Wang W, Chen Z, Xing L, Tang C, Ju X, Guo F, Deng J, Zhao Y, Tang J, Wang H, Zhao Z, Yin Z, Cao B, Wang X, Jiang C. IL-17 response mediates acute lung injury induced by the 2009 pandemic influenza A (H1N1) virus. Cell Res. 2012; 22 (3): 528-38.
167. Nakamura R, Maeda N, Shibata K, Yamada H, Kase T, Yoshikai Y. Interleukin-15 is critical in the pathogenesis of influenza a virus-induced acute lung injury. J Virol. 2010; 84 (11): 5574-82.
168. Sun J, Madan R, Karp CL, Braciale TJ. Effector T cells control lung inflammation during acute influenza virus infection by producing IL-10. Nat Med. 2009; 15 (3): 277-84.
169. Lin GH, Sedgmen BJ, Moraes TJ, Snell LM, Topham DJ, Watts TH. Endogenous 4-1BB ligand plays a critical role in protection from influenza-induced disease. J Immunol. 2009; 182 (2): 934-47.
170. Zhao Y, Zhang YH, Denney L, Young D, Powell TJ, Peng YC, Li N, Yan HP, Wang DY, Shu YL, Kendrick Y, McMichael AJ, Ho LP, Dong T. High levels of virus-specific CD4+ T cells predict severe pandemic influenza A virus infection. Am J Respir Crit Care Med. 2012; 186 (12): 1292-7.
171. Kilbourne ED, Smith C, Brett I, Pokorny BA, Johansson B, Cox N. The total influenza vaccine failure of 1947 revisited: major intrasubtypic antigenic change can explain failure of vaccine in a post-World War II epidemic. Proc Natl Acad Sci U S A. 2002; 99 (16): 10748-52.
172. He W, Wang W, Han H, Wang L, Zhang G, Gao B. Molecular basis of live-attenuated influenza virus. PLoS One. 2013; 8 (3): e60413.
173. Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, Kemble G, Connor EM. Live attenuated versus inactivated influenza vaccine in infants and young children. New Engl J Med. 2007; 356 (7): 685-96.
174. Seasonal influenza (flu). Live attenuated influenza vaccine [LAIV] (the nasal spray flu vaccine). Questions and answers [updated 2013 Oct 21; cited 2013 Dec 11]. Atlanta (GA): Centers for Disease Control and Prevention. Available at: http: //www. cdc. gov/flu/about/ qa/nasalspray. htm
175. He XS, Holmes TH, Zhang C, Mahmood K, Kemble GW, Lewis DB, Dekker CL, Greenberg HB, Arvin AM. Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J Virol. 2006; 80 (23): 11756-66.
176. Hemann EA, Kang SM, Legge KL. Protective CD8 T Cell-mediated immunity against influenza A virus infection following influenza virus-like particle vaccination. J Immunol. 2013; 191 (5): 2486-94.
177. Berthoud TK, Hamill M, Lillie PJ, Hwenda L, Collins KA, Ewer KJ, Milicic A, Poyntz HC, Lambe T, Fletcher HA, Hill AV, Gilbert SC. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin Infect Dis. 2011; 52 (1): 1-7.
178. Atsmon J, Kate-Ilovitz E, Shaikevich D, Singer Y, Volokhov I, Haim KY, Ben-Yedidia T. Safety and immunogenicity of multimeric-001-a novel universal influenza vaccine. J Clin Immunol. 2012; 32 (3): 595-603.
179. Lillie PJ, Berthoud TK, Powell TJ, Lambe T, Mullarkey C, Spencer AJ, Hamill M, Peng Y, Blais ME, Duncan CJ, Sheehy SH, Havelock T, Faust SN, Williams RL, Gilbert A, Oxford J, Dong T, Hill AV, Gilbert SC. Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans. Clin Infect Dis. 2012; 55 (1): 19-25.
180. Powell TJ, Peng Y, Berthoud TK, Blais ME, Lillie PJ, Hill AV, Rowland-Jones SL, McMichael AJ, Gilbert SC, Dong T. Examination of influenza specific T cell responses after influenza virus challenge in individuals vaccinated with MVA-NP+M1 vaccine. PLoS One. 2013; 8 (5): e62778.
181. Antrobus RD, Berthoud TK, Mullarkey CE, Hoschler K, Coughlan L, Zambon M, Hill AV, Gilbert SC. Coadministration of seasonal influenza vaccine and MVANP+ M1 simultaneously achieves potent humoral and cell mediated responses. Mol Ther. 2013 Jul 8. [Epub ahead of print]
182. Zhao RY, Mifsud NA, Xiao K, Chan KF, Oveissi S, Jackson HM, Dimopoulos N, Guillaume P, Knights AJ, Lowen T, Robson NC, Russell SE, Scotet E, Davis ID, Maraskovsky E, Cebon J, Luescher IF, Chen W. A novel HLA-B18 restricted CD8+ T cell epitope is efficiently cross-presented by dendritic cells from soluble tumor antigen. PLoS One. 2012; 7 (9): e44707.
183. Stoloff GA, Caparros-Wanderley W. Synthetic multiepitope peptides identified in silico induce protective immunity against multiple influenza serotypes. Eur J Immunol. 2007; 37 (9): 2441-9.
184. Flu-V: a ground-breaking universal influenza vaccine [c2010; cited 2013 Dec 11]. London: SEEK. Available at: http: //www. seekacure. com/products/Flu_V. html.